Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

Investors in Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw new options become available this week, for the June 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Investors in Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw new options become available today, for the January 2025 expiration. One of the key data points that goes into the price an option ...

Madrigal Pharmaceuticals is transitioning from clinical trials to market-ready solutions for non-alcoholic steatohepatitis and liver fibrosis. Read more here.

The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...

Madrigal Pharmaceuticals, Inc. (MDGL) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...